Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs.
Fifty-six adult beagle dogs (28 male, 28 female) were orally administered thalidomide at 43, 200, or 1000 mg/kg/day for 53 weeks. Sixteen (2/sex/dose group) and 32 (4/sex/dose group) dogs were euthanized and necropsied after 26 and 53 weeks of dosing, respectively. The remaining 8 animals (2/sex/group; high-dose and control groups) were dosed for 53 weeks, euthanized, and necropsied at 58 weeks after a 5-week recovery period. There were no deaths during the study. The only observed clinical signs attributable to thalidomide administration were green-colored urine, white-colored fecal residue presumed to be unchanged thalidomide, enlarged and/or blue coloration of female mammary tissue, and prolonged estrus. There were no thalidomide-related changes in body weights, food consumption, electrocardiography, ophthalmoscopy, neurological function, and endocrine function. The mostly slight and/or transient variations observed in some hematology and blood chemistry values of dosed dogs were considered to be toxicologically insignificant and were supported by the lack of histopathologic correlates. The only gross finding attributable to thalidomide was a yellow-green discoloration of the femur, rib, and/or calvarium that was observed at each euthanization interval including recovery. There was no microscopic correlate for this finding. No thalidomide-related microscopic changes were seen in any of the organs and tissues at 26 weeks. Mammary duct dilatation and/or glandular hyperplasia observed in females at 53 and 58 weeks and hepatic bile pigment exhibited by high-dose males at 53 weeks were microscopic changes considered to be thalidomide-related. There was no gross and histopathologic evidence of any tumors. In summary, thalidomide at up to 1000 mg/kg/day for 53 weeks did not induce any major systemic toxicity or tumors in dogs. The NOAEL was 200 mg/kg/day.
Teo
S K
SK
Celgene Corp., 7 Powder Horn Drive, Warren, New Jersey 07059, USA. steo@celgene.com
Evans
M G
MG
Brockman
M J
MJ
Ehrhart
J
J
Morgan
J M
JM
Stirling
D I
DI
Thomas
S D
SD
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology; D019963:Clinical Chemistry Tests; D003116:Color; D004285:Dogs; D004435:Eating / Q000187:drug effects; D004562:Electrocardiography; D005260:Female; D006403:Hematologic Tests; D006993:Hypnotics and Sedatives / Q000633:toxicity*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010865:Pilot Projects; D013792:Thalidomide / Q000633:toxicity*; D018675:Toxicity Tests
D006993:Hypnotics and Sedatives; D013792:Thalidomide